Tony Wood, Chief Scientific Officer, GSK: “We are pleased with ACIP's recommendation to expand the benefits of RSV immunization to more than 13 million adults aged 50-59 who are at increased risk for ...
The MONeT study enrolled individuals who had chronic pulmonary, cardiovascular, renal, hepatic, neurologic, hematologic or metabolic disorders. The Food and Drug Administration (FDA) has approved ...
The Comirnaty 2025-2026 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, a descendant of JN.1. The Food and Drug Administration (FDA) has approved Comirnaty ® (LP.8.1-adapted monovalent ...
Experts in vaccines and vaccination—including pediatricians—work together throughout the year to update the Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results